David Wofsy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Wofsy has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Betty Diamond
The Feinstein Institute for Medical Research, Manhasset
3 shared publications- Betty Diamond
Center of Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, USA
2 shared publications Jan L. Hillson
Bristol‐Myers Squibb Princeton New Jersey
2 shared publications- Alessandra Ida Celia
Rheumatology, Department of Clinical Internal, Anestesiological e Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy
1 shared publication - Andrea Fava
Division of Rheumatology, Johns Hopkins University , Baltimore, MD
1 shared publication - Anne Davidson
Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, and Donald and Barbara Zucker School of Medicine at Northwell/Hofstra 1 , Manhasset, NY
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 23 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (2)
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis
Lupus nephritis (LN) is a pathologically heterogenous autoimmune disease linked to end-stage kidney disease and mortality. Better therapeutic strategies are needed as only 30%–40% of patients completely respond to treatment. Noninvasive biomarkers of intrarenal inflammation may guide more precise approaches. Because urine collects the byproducts of kidney inflammation, we studied the urine proteomic profiles of 225 patients with LN (573 samples) in the longitudinal Accelerating Medicines Partnership in RA/SLE cohort. Urinary biomarkers of monocyte/neutrophil degranulation (i.e., PR3, S100A8, azurocidin, catalase, cathepsins, MMP8), macrophage activation (i.e., CD163, CD206, galectin-1), wound healing/matrix degradation (i.e., nidogen-1, decorin), and IL-16 characterized the aggressive proliferative LN classes and significantly correlated with histological activity. A decline of these biomarkers after 3 months of treatment predicted the 1-year response more robustly than proteinuria, the standard of care (AUC: CD206 0.91, EGFR 0.9, CD163 0.89, proteinuria 0.8). Candidate biomarkers were validated and provide potentially treatable targets. We propose these biomarkers of intrarenal immunological activity as noninvasive tools to diagnose LN and guide treatment and as surrogate endpoints for clinical trials. These findings provide insights into the processes involved in LN activity. This data set is a public resource to generate and test hypotheses and validate biomarkers.
- 23 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (2)
Top Cited PapersOpen AccessUrine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis
Lupus nephritis (LN) is a pathologically heterogenous autoimmune disease linked to end-stage kidney disease and mortality. Better therapeutic strategies are needed as only 30%–40% of patients completely respond to treatment. Noninvasive biomarkers of intrarenal inflammation may guide more precise approaches. Because urine collects the byproducts of kidney inflammation, we studied the urine proteomic profiles of 225 patients with LN (573 samples) in the longitudinal Accelerating Medicines Partnership in RA/SLE cohort. Urinary biomarkers of monocyte/neutrophil degranulation (i.e., PR3, S100A8, azurocidin, catalase, cathepsins, MMP8), macrophage activation (i.e., CD163, CD206, galectin-1), wound healing/matrix degradation (i.e., nidogen-1, decorin), and IL-16 characterized the aggressive proliferative LN classes and significantly correlated with histological activity. A decline of these biomarkers after 3 months of treatment predicted the 1-year response more robustly than proteinuria, the standard of care (AUC: CD206 0.91, EGFR 0.9, CD163 0.89, proteinuria 0.8). Candidate biomarkers were validated and provide potentially treatable targets. We propose these biomarkers of intrarenal immunological activity as noninvasive tools to diagnose LN and guide treatment and as surrogate endpoints for clinical trials. These findings provide insights into the processes involved in LN activity. This data set is a public resource to generate and test hypotheses and validate biomarkers.
- Open Access
- 16 March 2015
- Published by Wiley in Arthritis & Rheumatology
- Vol. 67 (5) , 1144-1146
Commentary: Crossing the Atlantic: The Euro‐Lupus Nephritis Regimen in North America
- 16 March 2015
- Published by Wiley in Arthritis & Rheumatology
- Vol. 67 (5) , 1144-1146
Open AccessCommentary: Crossing the Atlantic: The Euro‐Lupus Nephritis Regimen in North America
- 1 April 2013
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (suppl 2) , ii66-ii68
Recent progress in conventional and biologic therapy for systemic lupus erythematosus
The recent approval of belimumab for the treatment of systemic lupus erythematosus (SLE) ended a decade in which there was mounting optimism about the prospect for developing biologically based therapies for SLE. During this same period, steady progress had been made in understanding and applying conventional therapies for SLE. These advances in the use of conventional therapies provide an important frame of reference for evaluating the novel biologic therapies that are expected to emerge in the near future.
- 1 April 2013
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (suppl 2) , ii66-ii68
Recent progress in conventional and biologic therapy for systemic lupus erythematosus
The recent approval of belimumab for the treatment of systemic lupus erythematosus (SLE) ended a decade in which there was mounting optimism about the prospect for developing biologically based therapies for SLE. During this same period, steady progress had been made in understanding and applying conventional therapies for SLE. These advances in the use of conventional therapies provide an important frame of reference for evaluating the novel biologic therapies that are expected to emerge in the near future.
- Open Access
- 25 March 2013
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (6) , 1586-1591
Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials
Objective: Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end‐stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a large, multicenter trial of abatacept in lupus nephritis, to gain insight into which outcome measure, if any, was best able to discern differences among treatment groups.Methods: Study patients received either abatacept or placebo, on a background of mycophenolate mofetil and glucocorticoids. Using data from this trial, the following primary outcome measures at 24 and 52 weeks were compared: complete response rate, major clinical response rate, total response rate (complete plus partial response), improvement in proteinuria, improvement in estimated glomerular filtration rate, and frequency of treatment failure. Time to complete response was also evaluated.Results: Complete response rate, major clinical response rate, and time to complete response were the measures that best discriminated between the abatacept groups and placebo, and the sensitivities of these 3 measures were comparable. For these measures, sample sizes of 50 patients would have been sufficient to demonstrate a statistically significant difference between treatment and control at 52 weeks. Each of the other measures also discriminated between treatment and control, but much larger group sizes would have been required to determine statistical significance.Conclusion: The choice of primary outcome measure can substantially influence the ability to detect therapeutic benefit in lupus nephritis trials. This study suggests that complete response rate, major clinical response rate at 52 weeks, and time to complete response may be the most sensitive outcome measures for detecting differences among therapeutic regimens.
- 25 March 2013
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (6) , 1586-1591
Open AccessComparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials
Objective: Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end‐stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a large, multicenter trial of abatacept in lupus nephritis, to gain insight into which outcome measure, if any, was best able to discern differences among treatment groups.Methods: Study patients received either abatacept or placebo, on a background of mycophenolate mofetil and glucocorticoids. Using data from this trial, the following primary outcome measures at 24 and 52 weeks were compared: complete response rate, major clinical response rate, total response rate (complete plus partial response), improvement in proteinuria, improvement in estimated glomerular filtration rate, and frequency of treatment failure. Time to complete response was also evaluated.Results: Complete response rate, major clinical response rate, and time to complete response were the measures that best discriminated between the abatacept groups and placebo, and the sensitivities of these 3 measures were comparable. For these measures, sample sizes of 50 patients would have been sufficient to demonstrate a statistically significant difference between treatment and control at 52 weeks. Each of the other measures also discriminated between treatment and control, but much larger group sizes would have been required to determine statistical significance.Conclusion: The choice of primary outcome measure can substantially influence the ability to detect therapeutic benefit in lupus nephritis trials. This study suggests that complete response rate, major clinical response rate at 52 weeks, and time to complete response may be the most sensitive outcome measures for detecting differences among therapeutic regimens.
- 27 October 2012
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (11) , 3660-3665
Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions
Objective: Recent clinical trials in lupus nephritis have all used different criteria to assess complete response. The objective of this analysis was to compare several previously proposed criteria, using the same data set from a large trial of abatacept in lupus nephritis (IM101075). In so doing, we sought to determine which criteria are most sensitive to differences among treatment groups and to further examine the potential of abatacept in lupus nephritis.Methods: Patients in the IM101075 trial received abatacept at 1 of 2 different dose regimens or placebo, both on a background of mycophenolate mofetil and corticosteroids. Using data from this trial, we assessed rates of complete response at 12 months according to 5 sets of criteria, from 1) the trial protocol, 2) the Aspreva Lupus Management Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment with Rituximab (LUNAR) trial of rituximab, 4) an ongoing National Institutes of Health trial of abatacept (Abatacept and Cyclophosphamide Combination: Efficacy and Safety Study [ACCESS]), and 5) published recommendations of the American College of Rheumatology.Results: According to the complete response definition from the IM101075 study protocol, there was no difference among treatment groups in the IM101075 study. In contrast, according to the ALMS, LUNAR, and ACCESS criteria, rates of complete response among patients in the IM101075 study were higher in both treatment groups relative to control. The largest differences were obtained with use of the LUNAR criteria (complete response rate of 6% in the control group, compared to 22% and 24% in the 2 abatacept groups).Conclusion: The choice of definition of complete response can determine whether a lupus nephritis trial is interpreted as a success or a failure. The results of this analysis provide an evidence‐based rationale for choosing among alternative definitions and offer a strong rationale for conducting further studies of abatacept in lupus nephritis.
- 27 October 2012
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (11) , 3660-3665
Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions
Objective: Recent clinical trials in lupus nephritis have all used different criteria to assess complete response. The objective of this analysis was to compare several previously proposed criteria, using the same data set from a large trial of abatacept in lupus nephritis (IM101075). In so doing, we sought to determine which criteria are most sensitive to differences among treatment groups and to further examine the potential of abatacept in lupus nephritis.Methods: Patients in the IM101075 trial received abatacept at 1 of 2 different dose regimens or placebo, both on a background of mycophenolate mofetil and corticosteroids. Using data from this trial, we assessed rates of complete response at 12 months according to 5 sets of criteria, from 1) the trial protocol, 2) the Aspreva Lupus Management Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment with Rituximab (LUNAR) trial of rituximab, 4) an ongoing National Institutes of Health trial of abatacept (Abatacept and Cyclophosphamide Combination: Efficacy and Safety Study [ACCESS]), and 5) published recommendations of the American College of Rheumatology.Results: According to the complete response definition from the IM101075 study protocol, there was no difference among treatment groups in the IM101075 study. In contrast, according to the ALMS, LUNAR, and ACCESS criteria, rates of complete response among patients in the IM101075 study were higher in both treatment groups relative to control. The largest differences were obtained with use of the LUNAR criteria (complete response rate of 6% in the control group, compared to 22% and 24% in the 2 abatacept groups).Conclusion: The choice of definition of complete response can determine whether a lupus nephritis trial is interpreted as a success or a failure. The results of this analysis provide an evidence‐based rationale for choosing among alternative definitions and offer a strong rationale for conducting further studies of abatacept in lupus nephritis.
- 1 March 2010
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 6 (3) , 124-125
Belimumab for systemic lupus erythematosus: breaking through?
- 1 March 2010
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 6 (3) , 124-125
Belimumab for systemic lupus erythematosus: breaking through?
- 1 August 2001
- Published by Wiley in Arthritis & Rheumatism
- Vol. 44 (8) , 1730-1735
The immune tolerance network and rheumatic disease: Immune tolerance comes to the clinic
First page of article
- 1 August 2001
- Published by Wiley in Arthritis & Rheumatism
- Vol. 44 (8) , 1730-1735
The immune tolerance network and rheumatic disease: Immune tolerance comes to the clinic
First page of article